<DOC>
	<DOCNO>NCT01711073</DOCNO>
	<brief_summary>A phase I trial study safety mobilization stem cell G-CSF Mozobil patient chronic liver disease .</brief_summary>
	<brief_title>Mobilization Stem Cells With G-CSF Mozobil Patients With End Stage Liver Disease</brief_title>
	<detailed_description>Liver cirrhosis human represent end stage chronic liver injury . Supply `` new '' stem cell liver could regenerate hepatocytes restore lose function . Delivery Mesenchymal Stem Cells ( MSCs ) show animal model limit clinical trial result improve liver disease ( MELD ) score . In preclinical study demonstrate combination G-CSF plus Mozobil effectively mobilize hematopoietic stem cell ( HSCs ) MSCs peripheral circulation . While G-CSF mobilize HSCs . The clinical trial test safety treat patient end stage liver disease G-CSF Mozobil mobilize MSCs peripheral circulation .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>End Stage Liver Disease</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Patients clinical diagnosis cirrhosis Age great equal 18 year MELD score less equal 12 able provide inform consent HIV HBsAg seronegative Platelet count &gt; 50,000 , WBC count &gt; 2,000 No history malignancy within last 5 year , except nonmelanoma skin cancer cervical carcinoma situ No lesion suspicious liver cancer CT and/or MRI within prior 4 month Patients acute subacute onset liver disease Patients receive liver transplant Age &lt; 18 MELD score &gt; 12 Patients whose MELD score currently less equal 12 history prior deterioration MELD score &gt; 12 Unable provide inform consent Patients HIV HBsAg seropositivity Pregnant lactating female Enrolled another research protocol Any condition precludes serial follow Patients history malignancy within last 5 year , except nonmelanoma skin cancer cervical carcinoma situ Any lesion suspicious liver cancer CT and/or MRI within prior 4 month Patients palpable splenomegaly physical examination ANy condition investigator opinion would likely increase risk particpation would likely confound interpretation data</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>